Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery

Venous thromboembolism - dabigatran: review decision - August 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 58 KB)

Venous thromboembolism - dabigatran: review proposal - June 2011 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 52 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Venous thromboembolism - dabigatran: final appraisal determination information

Venous thromboembolism - dabigatran: final appraisal determination

Venous thromboembolism - dabigatran: final appraisal determination (PDF 131 KB)

Venous thromboembolism - dabigatran: evaluation report

Venous thromboembolism - dabigatran: evidence review group report

Venous thromboembolism - dabigatran: evidence review group report (PDF 1.24 MB)

Venous thromboembolism - dabigatran: pre-meeting briefing

Venous thromboembolism - dabigatran: pre-meeting briefing (PDF 83 KB)

Venous thromboembolism - dabigatran: non-manufacturer submissions

Anticoagulation Europe

Anticoagulation Europe (PDF 43 KB)

British Orthopaedic Association

British Orthopaedic Association (PDF 32 KB)

British Society for Haemostasis and Thrombosis

British Society for Haemostasis and Thrombosis (PDF 33 KB)

Joint submission from British Society for Haematology and Royal College of Pathologists

Joint submission from British Society for Haematology and Royal College of Pathologists (PDF 62 KB)

Royal College of Nursing

Royal College of Nursing (PDF 31 KB)

Venous thromboembolism - dabigatran: manufacturer submission

Venous thromboembolism - dabigatran: manufacturer submission (PDF 1.51 MB)

Venous thromboembolism - dabigatran: clarification letters

Manufacturer response to clarification letter 1

Manufacturer response to clarification letter 1 (PDF 437 KB)

Manufacturer response to clarification letter 2

Manufacturer response to clarification letter 2 (PDF 108 KB)

NICE clarification letter

NICE clarification letter (PDF 75 KB)

Mrs Sharron Rawden

Venous thromboembolism - dabigatran: final scope

Venous thromboembolism - dabigatran: response to consultee and commentator comments on the draft scope

Venous thromboembolism - dabigatran: response to consultee and commentator comments on the provisional matrix

Venous thromboembolism - dabigatran: list of stakeholders